The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Novo Nordisk (NVO), the maker of blockbuster weight-loss and diabetes drugs Wegovy and Ozempic, has entered an agreement with ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Ozempic sales were a bit lower than expected in the quarter at DKK 29.8 billion, while Wegovy sales were higher at DKK 17.3 ...

Novo Nordisk scientist Lotte Knudsen, whose research led to Ozempic and Wegovy, started her career developing laundry ...

Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.